請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69673
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建煒(K.Arnold Chan) | |
dc.contributor.author | Hui-Min Lin | en |
dc.contributor.author | 林卉敏 | zh_TW |
dc.date.accessioned | 2021-06-17T03:23:17Z | - |
dc.date.available | 2018-12-31 | |
dc.date.copyright | 2018-08-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-06-13 | |
dc.identifier.citation | 1. Taiwan National Adverse Drug Reactions Reporting System. (https://adr.fda.gov.tw/Manager/WebLogin.aspx). (Accessed May, 3rd 2018).
2. FDA Adverse Event Reporting System (FAERS). (https://www.fda.gov/Drugs/InformationOnDrugs/ucm135151.htm). (Accessed May, 3rd 2018). 3. Rawson NS, Pearce GL, Inman WH. Prescription-event monitoring: methodology and recent progress. Journal of clinical epidemiology 1990;43(5):509-22. 4. FDA's Sentinel Initiative. (https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm). (Accessed May, 3rd 2018). 5. Platt R, Wilson M, Chan KA, et al. The New Sentinel Network — Improving the Evidence of Medical-Product Safety. New England Journal of Medicine 2009;361(7):645-7. 6. Chrischilles EA, Gagne JJ, Fireman B, et al. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiology and drug safety 2018;27(3):263-71. 7. Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. New England Journal of Medicine 2013;368(14):1272-4. 8. Go AS, Singer DE, Toh S, et al. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: A retrospective cohort study. Annals of internal medicine 2017;167(12):845-54. 9. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158(9):915-20. 10. Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiology and drug safety 2013;22(1):1-6. 11. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Current epidemiology reports 2015;2(4):221-8. 12. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (Cambridge, Mass) 2008;19(6):766-79. 13. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Archives of internal medicine 2012;172(20):1582-9. 14. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131(2):157-64. 15. Vandenbroucke J, Pearce N. Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology? Am J Epidemiol 2015;182(10):826-33. 16. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. Journal of clinical epidemiology 1994;47(7):731-7. 17. McMahon AD, MacDonald TM. Design issues for drug epidemiology. British journal of clinical pharmacology 2000;50(5):419-25. 18. Gokhale M, Buse JB, Pate V, et al. More realistic power estimation for new user, active comparator studies: an empirical example. Pharmacoepidemiology and drug safety 2016;25(4):462-6. 19. Suissa S, Moodie EE, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiology and drug safety 2017;26(4):459-68. 20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine 2009;361(12):1139-51. 21. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine 2009;361(24):2342-52. 22. Investigators TE. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine 2010;363(26):2499-510. 23. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine 2011;365(11):981-92. 24. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine 2011;365(10):883-91. 25. Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine 2013;369(9):799-808. 26. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine 2013;369(22):2093-104. 27. da Silva RMFL. Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation. Cardiovascular & Hematological Agents in Medicinal Chemistry 2014;12(1):3-8. 28. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scandinavian journal of public health 2011;39(7 Suppl):38-41. 29. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clinical Epidemiology 2015;7:449-90. 30. Lai CL, Chen HM, Liao MT, et al. Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. Journal of the American Heart Association 2017;6(4). 31. Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: Contemporary findings in real-life Danish patients. Journal of the American Heart Association 2017;6(2). 32. Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. European heart journal Cardiovascular pharmacotherapy 2017;3(1):28-36. 33. Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology 2016;68(13):1389-401. 34. Chan YH, Yen KC, See LC, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke 2016;47(2):441-9. 35. Hsiao FY, Yang CL, Huang YT, et al. Using Taiwan's national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal 2007;15(2):99-108. 36. Cheng CL, Lee CH, Chen PS, et al. Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan. Journal of Epidemiology 2014;24(6):500-7. 37. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety 2011;20(3):236-42. 38. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. International journal of epidemiology 2000;29(2):336-43. 39. Eric WL, L.J. W, David AA, et al. Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations. Survival Analysis: State of the Art 1992;211:237-47. 40. Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016;115(1):152-60. 41. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association 2016;5(6). 42. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiology and drug safety 2005;14(7):465-76. 43. Wang SV, He M, Jin Y, et al. A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiology and drug safety 2017;26(12):1507-12. 44. Wang SV, Jin Y, Fireman B, et al. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. American journal of epidemiology 2018:kwy049-kwy. 45. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and Warfarin for secondary prevention of stroke in Atrial fibrillation patients: A nationwide cohort study. American Journal of Medicine 2014;127(12):1172-8.e5. 46. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology (Cambridge, Mass) 2004;15(5):615-25. 47. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012;175(4):250-62. 48. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (Clinical research ed) 2015;350:h1857. 49. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thrombosis and Haemostasis 2015;114(6):1290-8. 50. Gorst-Rasmussen A, Lip GYH, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiology and drug safety 2016;25(11):1236-44. 51. Li X, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in 'real-world' clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017. 52. Forslund T, Wettermark B, Andersen M, et al. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2017. 53. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010;122(22):2246-53. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69673 | - |
dc.description.abstract | 研究背景:
新藥於上市後須積極監測安全與療效,因此需要設計完善的藥物流行病學研究協助了解一般臨床藥品使用與治療情況。過去流行病學研究使用的new user design和prevalent user design各有優缺於觀察新上市藥品之療效與安全性。臨床上,若病人為診斷疾病後使用新上市藥品,這些藥品使用者將稱之為新藥new user。另有病人於新藥上市前即被診斷疾病而使用了一陣子現有治療並在新藥上市後才改使用新藥,此類病人即視為新藥switcher。本研究改良並使用新研究方法prevalent new user design於抗凝血劑藥品為一範例,作為新上市藥品研究設計之討論。 研究方法: 本研究使用2011年至2015年台灣全民健康保險資料,並且以新發非瓣膜性心房震顫病人成立初步研究世代。再因應當病人開始使用新藥dabigatran處方時建立一個暴露集合(exposure set),並納入warfarin處方使用者擁有與dabigatran使用者類似之過往抗凝血劑經驗於暴露集合中。利用傾向分數之計算,於集合中配對出傾向分數最近的dabigatran和warfarin處方,並以該處方使用者建立出研究世代。最後於此研究世代探討腦出血、腸胃道出血、栓塞性中風和死亡風險比較。 研究結果: 初步研究世代包含30,168位心房震顫病人,並在暴露集合和傾向分數配對設計後納入了22,334位追蹤對象於研究世代。相較於warfarin使用者,dabigatran使用者有較低的腦出血(相對危險(HR)=0.50; 95% 信賴區間(CI): 0.39, 0.65)、腸胃道出血(HR=0.77; 95%CI: 0.67, 0.88)以及死亡風險(HR=0.58; 95%CI: 0.54,0.63)。而對於栓塞性中風兩者風險無異。 結論: Prevalent new user 研究設計目標為在新藥藥品上市時盡量納入所有新藥藥品使用者包含new users和switchers。利用暴露集合之設計更是能針對switchers控制於新藥使用前之其他藥品暴露所造成的影響並且偵測過去其他藥品使用時發生的研究事件。總結,此方法可提供新上市藥品更為精緻的安全與療效分析亦可提供不同型態新藥品使用者之分析結果。 | zh_TW |
dc.description.abstract | Background:
Timely safety and effectiveness outcome evaluation for new drugs were expected from well-designed pharmacoepidemiolgy studies. New user design and prevalent user design each shared its shortcomings especially when studying recently launched new drugs. In clinical practice, patients offered a new drug once being diagnosed would be considered as a new drug new user. Whereas patients treated with an old drug and switched to the new drug afterwards would be considered as a new drug switcher. Thus an innovative study design, prevalent new user, was suggested to study new drugs encompassing both new users and switchers. We implemented the design with modification and demonstrated study design concerns in practice on a novel drug, dabigatran, among oral anticoagulants for illustration. Methods: An incident non-valvular atrial fibrillation base cohort was constructed in this study utilizing Taiwan National Health Insurance data from 2011 through 2015. When a patient initiated dabigatran, warfarin prescriptions with comparable prior oral anticoagulant to the dabigatran initiating prescription would be included in an exposure set. Propensity score (PS) estimated within the exposure set for the dabigatran and warfarin prescriptions were matched to select the dabigatran and warfarin users to be included in the study cohort. Intracranial hemorrhage, gastrointestinal bleeding, ischemic stroke and all-cause mortality were evaluated among patients in the study cohort. Results: There were 30,168 patients included in the base cohort. After constructing exposure sets and PS matching, 22,334 patients were included in the study cohort for safety and effectiveness outcome evaluation. Decrease in risk of intracranial hemorrhage (hazard ratio(HR)=0.50; 95% confidence interval(CI): 0.39, 0.65), gastrointestinal bleeding (HR=0.77; 95%CI: 0.67, 0.88) and all-cause mortality (HR=0.58; 95%CI: 0.54,0.63) were observed among dabigatran prevalent new users comparing with the matched warfarin users. Similar effectiveness in stroke prevention were observed among dabigatran and warfarin users. Conclusion: Prevalent new user design intended to incorporate sizeable new drug users, including both new users and switchers, soon after a drug was introduced. Exposure sets applied were to control for previous drug use experience as well as taking into account of events occurred during the prior drug exposure period among switchers. As a result, refined analyses were carried out among dabigatran users as well as estimates among new users and switchers. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:23:17Z (GMT). No. of bitstreams: 1 ntu-107-R04849049-1.pdf: 1562387 bytes, checksum: 9346936f6d6c724350fe698dc83e4f31 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | Table of content
口試委員會審定書 i 誌謝 ii First Part of Master Thesis iii 中文摘要 iii Abstract v 1. Background 1 1.1 Introduction 1 1.2 New user design and prevalent user design 2 1.3 Oral anticoagulant studies as an example 3 1.3.1 Literature review 4 1.3.2 Reviewed studies 4 1.3.3 Review of oral anticoagulant study designs 5 1.4 Oral anticoagulant illustration 5 2. Methods 7 2.1 Data source 7 2.2 Drug user terminology 8 2.3 Non-valvular atrial fibrillation base cohort 8 2.4 Time and prescription-based exposure sets 9 2.5 Propensity score(PS) and blocks 9 2.6 Propensity score matching 10 2.7 Clinical outcomes 10 2.8 Statistical analysis 11 3. Results 13 3.1 Disposition of dabigatran prevalent new users 13 3.2 Base cohort 13 3.3 Exposure sets 14 3.4 Propensity score 14 3.5 After propensity score matching 14 3.6 Effectiveness and safety analyses 15 3.7 Further analyses on data violating proportional hazard assumption 16 4. Discussion 17 4.1 Main findings and previous studies in Taiwan 17 4.2 Method implementation and strengths 18 4.3 Limitations 20 4.4 Conclusion 21 Tables 22 Figures 56 References 66 Second Part of Master Thesis 69 | |
dc.language.iso | en | |
dc.title | 新上市藥品新使用者研究設計:以抗凝血劑作為範例 | zh_TW |
dc.title | Modified Prevalent New User Design:
An Illustration with Oral Anticoagulants | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 杜裕康(Yu-Kang Tu) | |
dc.contributor.oralexamcommittee | 賴超倫(Chao-Lun Lai),東雅惠(Yaa-Hui Dong) | |
dc.subject.keyword | Prevalent new user design,暴露集合,傾向分數配對, | zh_TW |
dc.subject.keyword | Prevalent new user design,exposure sets,propensity score matching, | en |
dc.relation.page | 69 | |
dc.identifier.doi | 10.6342/NTU201800934 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-06-13 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 1.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。